Standard BioTools

361 articles about Standard BioTools

• Standard BioTools to Present at the Jefferies London Healthcare Conference

  11/2/2023

  Standard BioTools Inc. today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated Q&A session at the Jefferies London Healthcare Conference on Wednesday, November 15 at 11:00 a.m. GMT.

• Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

  10/4/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, a leader in data-driven proteomics technology, announced that they have entered into a definitive agreement to combine in an all-stock merger.

• Standard BioTools Reports Second Quarter 2023 Financial Results

  8/8/2023

  Standard BioTools Inc. reported financial results for the second quarter ended June 30, 2023.

• Standard BioTools to Participate in Upcoming Investor Conferences - July 26, 2023

  7/26/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced Company management will participate in the following investor conferences:

• Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

  7/25/2023

  Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of the market.

• Standard BioTools to Participate in Upcoming June 2023 Investor Conferences

  6/14/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced Company management will participate in the following investor conferences.

• Standard BioTools to Present at the Jefferies 2023 Healthcare Conference

  5/25/2023

  Standard BioTools Inc. announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET.

• Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

  5/18/2023

  Standard BioTools Inc. today announced the launch of NGS library preparation functionality on the X9™ High-Throughput Genomics System.

• Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  5/15/2023

  Standard BioTools Inc. announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer.

• Standard BioTools Reports First Quarter 2023 Financial Results

  5/9/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – reported financial results for the first quarter ended March 31, 2023.

• Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results

  4/25/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the market.

• Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2023

  4/20/2023

  Standard BioTools Inc. announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards, effective as of April 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan, as a material inducement to four individuals entering into employment with Standard BioTools.

• Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology

  4/17/2023

  Standard BioTools Inc. today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando.

• Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  3/22/2023

  Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools Inc.

• Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors

  3/15/2023

  Standard BioTools Inc., driven by a bold purpose announced the appointment of Fenel Eloi to its Board of Directors.

• Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

  3/14/2023

  Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET.

• Standard BioTools to Present at 43rd Annual Cowen Health Care Conference

  3/1/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET.

• Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 21, 2023

  2/21/2023

  Standard BioTools Inc. announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan, as a material inducement to four individuals entering into employment with Standard BioTools™.

• Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook

  2/14/2023

  Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the fourth quarter and year ended December 31, 2022.

• Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update

  1/9/2023

  Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced preliminary fourth quarter and full year 2022 revenue and provided a business update.